In Silico Polypharmacological Profiling of Lupeol and 1-Heptatriacontanol from Probiotic Limosilactobacillus reuteri GM4 and Streptococcus equinus WC1 against Colorectal Cancer-Associated Targets

Cancer is a disease of broken signals, where cells that should stop growing instead multiply out of control. In the colon, this uncontrolled growth leads to colorectal cancer, a leading cause of death worldwide. While modern medicine offers treatments like surgery and chemotherapy, these approaches can be harsh, and cancer cells often find ways to resist them. This has led scientists to look for new solutions in unexpected places, including the trillions of tiny bacteria living inside the human gut. These microbes, known as the gut microbiota, do more than just help digest food; they produce a vast array of chemical compounds that can influence human health. Some of these bacterial byproducts have shown promise in fighting disease, acting as natural tools that might one day help stop cancer cells from spreading or force them to die.

To understand how these bacterial chemicals might work, researchers turned to a powerful computer-based method called molecular docking. Imagine trying to find a key that fits a specific lock; in the body, the "locks" are proteins that control cell growth, and the "keys" are chemical molecules. If a molecule fits tightly into a protein's active site, it can change how that protein behaves. By simulating this fitting process on a computer, scientists can predict which bacterial chemicals might interact with the proteins involved in colorectal cancer. This approach allows researchers to screen thousands of potential candidates quickly, narrowing down the list to the most promising ones before testing them in a lab or in living organisms.

In a recent study, researchers Mona A. Ashour and Khaled Metwally from Ain Shams University in Egypt explored this possibility using two specific strains of beneficial bacteria: Limosilactobacillus reuteri GM4 and Streptococcus equinus WC1. These bacteria are part of the normal gut community and are known for their ability to support health. The team first grew these bacteria in a controlled environment and collected the liquid they produced, which contains the chemicals the bacteria secrete. Using a technique that separates and identifies chemicals based on their weight and structure, they analyzed the mixture to see what was inside. They found that the bacteria produced several complex molecules, but two stood out as the most abundant and interesting: a compound called lupeol and another called 1-heptatriacontanol. Lupeol made up nearly 15 percent of the volatile chemicals from one strain, while 1-heptatriacontanol appeared at about 5.5 percent in the other.

With these two chemicals identified, the researchers then asked a critical question: could they bind to the proteins that drive colorectal cancer? They selected ten different human proteins known to be involved in cancer development, including those that control cell division, manage hormones, and repair damaged DNA. Using computer simulations, they modeled how lupeol and 1-heptatriacontanol would interact with each of these ten targets. The results showed a clear difference between the two chemicals. Lupeol was a much better fit for the cancer-related proteins than 1-heptatriacontanol. In eight out of the ten cases, lupeol bound more tightly, with the strength of the bond varying from moderate to very strong. The strongest interaction occurred with a protein called HSD11B1, which helps regulate stress hormones in the body. In the simulation, lupeol settled into this protein's active site with a binding energy of negative 11.0 kilocalories per mole, a value that indicates a very stable connection. In contrast, 1-heptatriacontanol, which is essentially a long, flexible chain of carbon atoms, struggled to form stable connections with most of the targets, often showing much weaker binding scores.

The researchers examined the details of these interactions to understand why lupeol was so effective. They found that lupeol has a rigid, multi-ring structure that acts like a solid block, allowing it to nestle comfortably into the hollow pockets of the proteins. It formed numerous contacts with the surrounding amino acids, mostly through hydrophobic interactions, which are forces that push non-water-loving parts of molecules together. In some cases, like with the protein CDC25B, lupeol also formed a specific hydrogen bond, a stronger type of connection, with a single amino acid in the protein. This combination of a solid shape and multiple contact points allowed lupeol to hold on tightly. On the other hand, 1-heptatriacontanol, with its long and floppy chain, lacked the rigid structure needed to lock into place effectively. It could only form weak, loose connections, which explains why it performed poorly in the simulations.

One of the most significant findings was the potential impact on HSD11B1. This protein is known to be involved in metabolic syndrome and has been linked to cancer cell survival. The simulation suggested that lupeol could block this protein's activity, which might disrupt the signals that help cancer cells grow. The study also highlighted interactions with other important targets, such as the androgen receptor, which is involved in cell growth, and TRPM8, a channel that senses cold and pain. While the computer models showed that lupeol could fit into these proteins, the researchers were careful to note that these are predictions. The simulations do not prove that lupeol actually stops these proteins from working in a living human body, nor do they show that it kills cancer cells directly. The study explicitly states that these results are a starting point, a way to generate hypotheses that need to be tested with real-world experiments.

The authors concluded that while both chemicals came from the same source, lupeol is the far more promising candidate for further study. Its ability to bind to a wide variety of cancer-related proteins suggests it might work through multiple pathways at once, a strategy that could be useful against complex diseases like cancer. However, the paper makes it clear that this is only the first step. The findings are purely computational, based on mathematical models of how molecules might interact. To move from a computer screen to a real treatment, scientists would need to confirm these interactions in a lab, test how the body processes the chemical, and see if it actually slows down or stops cancer growth in living systems. For now, the study offers a compelling reason to look closer at the chemicals produced by gut bacteria, suggesting that nature may have already provided some of the tools needed to fight disease, hidden in plain sight within our own microbiome.